Skip to content
AnalystLens

BridgeBio Pharma 8-K Report, Corporate Update (Sep 11, 2024)

Reports
Other Events·Exhibits & Filings
Filing Date
Filed September 11, 2024
Period End
September 10, 2024
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’20Feb ’20
  2. Leadership change8-K · Oct ’21Oct ’21
  3. Material agreement8-K · Sep ’23Sep ’23
  4. Material agreement8-K · Aug ’26Aug ’26

Summary

Summary of the 8-K filed September 11, 2024. Cited figures are marked; the original filing is the authoritative source.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported topline results on September 10, 2024 from the Phase 1/2 open-label ADventure study of BBP-631, its investigational AAV5 gene therapy for congenital adrenal hyperplasia (CAH).

The company stated that increased endogenous cortisol production was achieved in all patients at higher doses, with maximum changes from baseline post-ACTH stimulation of 4.7 μg/dL and 6.6 μg/dL at the two highest dose levels, and that BBP-631 was well tolerated with no treatment-related serious adverse events reported. Despite these results, BridgeBio said the data do not warrant additional capital investment at this time. The company will no longer pursue development of BBP-631 for CAH, will reduce the gene therapy budget by more than $50 milliona, and is actively seeking partnership opportunities to support future development of BBP-631 or next-generation gene therapies for CAH.

Management described the data as "not yet transformational" while noting the study showed for the first time that people with CAH can make their own cortisol and that gene therapy can be safely administered in this population. The company also said it will reserve gene therapy for priority targets it cannot treat any other way, and that it is eager to work with the FDA and the Canavan community toward bringing its therapy to families with Canavan disease.

Key Highlights

  1. BBP-631 (AAV5 gene therapy for CAH) produced increased endogenous cortisol production in all patients at higher doses, with cortisol levels as high as 11 μg/dL achieved.
  2. Maximum post-ACTH stimulation changes from baseline of 4.7 μg/dL and 6.6 μg/dL were observed at the two highest dose levels.
  3. At the highest dose levels, sustained 11-deoxycortisol averaged a 55-fold increase from baseline, with a maximum of 99-fold; 17-hydroxyprogesterone reductions reached a maximum of 95%, with the majority of patients achieving reductions of 50% or more.
  4. BBP-631 was well tolerated, with only mild to moderate treatment-emergent adverse events and no treatment-related serious adverse events reported.
  5. BridgeBio will no longer pursue development of BBP-631 for CAH and is seeking partnership opportunities for BBP-631 or next-generation CAH gene therapies.
  6. The gene therapy budget will be reduced by more than $50 million, with gene therapy reserved for priority targets that cannot be treated any other way.
  7. The company cited an estimated 75,000 CAH cases in the United States and European Union as the basis for continued unmet need.

Frequently Asked Questions

  1. Why is BridgeBio ending development of BBP-631 for CAH if the trial showed positive results?

    The company stated that the results did not meet the threshold to warrant additional capital investment at this time, consistent with its capital allocation principles. Management described the data as not yet transformational, although the study showed that people with CAH can make their own cortisol and that gene therapy can be safely administered in this population.

  2. How much will BridgeBio reduce its gene therapy spending?

    The Chief Financial Officer, Brian Stephenson, said BridgeBio will reduce the gene therapy budget by more than $50 million.

  3. Is BBP-631 safe based on the study results?

    The company reported that BBP-631 was well tolerated, with only mild to moderate treatment-emergent adverse events and no treatment-related serious adverse events reported.

  4. Will BridgeBio continue to work on CAH gene therapy?

    BridgeBio will no longer pursue development of BBP-631 for CAH on its own, but it is actively seeking partnership opportunities to support future development of BBP-631 or next-generation gene therapies for CAH.

  5. What is the size of the market opportunity for CAH?

    The company estimated more than 75,000 cases of CAH in the United States and European Union and stated that the disease still has significant unmet need.